Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine
- Development stage
- Phase 3
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (marketed under the brand name Nimenrix) is a quadrivalent conjugate vaccine originally developed by GSK and later acquired by Pfizer. It is indicated for active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135, and Y. The vaccine consists of purified capsular polysaccharides from each of the four serogroups, each individually conjugated to a tetanus toxoid carrier protein. This conjugation converts the T-cell-independent polysaccharide antigens into T-cell-dependent antigens, enhancing immunogenicity and inducing immunological memory, particularly in infants and young children. It is administered via intramuscular injection.
- Brand names
- Nimenrix
- Other names
- meningococcal groups A, C, W-135 and Y conjugate vaccinemeningococcal group A, C, W-135 and Y conjugate vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)TT (Tetanus toxoid)
Beyond the preview
Go deeper on meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine.